Calcitonin gene-related peptide (CGRP): role in migraine pathophysiology and therapeutic targeting

Anne-Sophie Wattiez; Levi P Sowers; Andrew F Russo

doi:10.1080/14728222.2020.1724285

Back

Calcitonin gene-related peptide (CGRP): role in migraine pathophysiology and therapeutic targeting

Journal article

Peer reviewed

Calcitonin gene-related peptide (CGRP): role in migraine pathophysiology and therapeutic targeting

Anne-Sophie Wattiez, Levi P Sowers and Andrew F Russo

Expert opinion on therapeutic targets, Vol.24(2), pp.91-100

02/2020

DOI: 10.1080/14728222.2020.1724285

PMCID: PMC7050542

PMID: 32003253

Files and links (1)

url

https://www.ncbi.nlm.nih.gov/pmc/articles/7050542View

Open Access

Abstract

: The neuropeptide calcitonin gene-related peptide (CGRP) is recognized as a critical player in migraine pathophysiology. Excitement has grown regarding CGRP because of the development and clinical testing of drugs targeting CGRP or its receptor. While these drugs alleviate migraine symptoms in half of the patients, the remaining unresponsive half of this population creates an impetus to address unanswered questions that exist in this field. : We describe the role of CGRP in migraine pathophysiology and CGRP-targeted therapeutics currently under development and in use. We also discuss how a second CGRP receptor may provide a new therapeutic target. : CGRP-targeting drugs have shown a remarkable safety profile. We speculate that this may reflect the redundancy of peptides within the CGRP family and a second CGRP receptor that may compensate for reduced CGRP activity. Furthermore, we propose that an inherent safety feature of peptide-blocking antibodies is attributed to the fundamental nature of peptide release, which occurs as a large bolus in short bursts of volume transmission. These facts support the development of more refined CGRP therapeutic drugs, as well as drugs that target other neuropeptides. We believe that the future of migraine research is bright with exciting advances on the horizon.

Receptors, Calcitonin Gene-Related Peptide - drug effects

Animals

Humans

Migraine Disorders - physiopathology

Drug Development

Calcitonin Gene-Related Peptide - metabolism

Molecular Targeted Therapy

Migraine Disorders - drug therapy

Receptors, Calcitonin Gene-Related Peptide - metabolism

Details

Title: Subtitle: Calcitonin gene-related peptide (CGRP): role in migraine pathophysiology and therapeutic targeting
Creators: Anne-Sophie Wattiez - VA Center for the Prevention and Treatment of Visual Loss, VA Medical Center, Iowa City, IA, USA
Levi P Sowers - VA Center for the Prevention and Treatment of Visual Loss, VA Medical Center, Iowa City, IA, USA
Andrew F Russo - Department of Neurology, University of Iowa, Iowa City, IA, USA
Resource Type: Journal article
Publication Details: Expert opinion on therapeutic targets, Vol.24(2), pp.91-100
DOI: 10.1080/14728222.2020.1724285
PMID: 32003253
PMCID: PMC7050542
NLM abbreviation: Expert Opin Ther Targets
ISSN: 1472-8222
eISSN: 1744-7631
Publisher: England
Grant note: R01 NS075599 / NINDS NIH HHS RF1 NS113839 / NINDS NIH HHS
Language: English
Date published: 02/2020
Academic Unit: Neurology; Molecular Physiology and Biophysics; Stead Family Department of Pediatrics; Iowa Neuroscience Institute; Craniofacial Anomalies Research Center; Neurology (Pediatrics)
Record Identifier: 9984070362602771

Metrics

20 Record Views

131 Times Cited - Web of Science

See more details